Getinge AB (publ) (GETI-B.ST)
SEK 174.85
(2.01%)
SEK 174.85
(2.01%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 31.82 Billion SEK | 12.5% |
| 2022 | 28.29 Billion SEK | 4.59% |
| 2021 | 27.04 Billion SEK | -9.29% |
| 2020 | 29.81 Billion SEK | 12.27% |
| 2019 | 26.55 Billion SEK | 9.88% |
| 2018 | 24.17 Billion SEK | 7.45% |
| 2017 | 22.49 Billion SEK | -24.4% |
| 2016 | 29.75 Billion SEK | -1.58% |
| 2015 | 30.23 Billion SEK | 13.37% |
| 2014 | 26.66 Billion SEK | 5.47% |
| 2013 | 25.28 Billion SEK | 4.28% |
| 2012 | 24.24 Billion SEK | 10.95% |
| 2011 | 21.85 Billion SEK | -1.43% |
| 2010 | 22.17 Billion SEK | -2.82% |
| 2009 | 22.81 Billion SEK | 18.39% |
| 2008 | 19.27 Billion SEK | 17.19% |
| 2007 | 16.44 Billion SEK | 26.49% |
| 2006 | 13 Billion SEK | 9.43% |
| 2005 | 11.88 Billion SEK | 9.11% |
| 2004 | 10.88 Billion SEK | 18.87% |
| 2003 | 9.16 Billion SEK | 6.02% |
| 2002 | 8.64 Billion SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 8.3 Billion SEK | 10.54% |
| 2024 Q3 | 7.87 Billion SEK | -5.24% |
| 2024 Q1 | 7.51 Billion SEK | -24.13% |
| 2023 Q1 | 7.14 Billion SEK | -15.97% |
| 2023 Q4 | 9.9 Billion SEK | 30.18% |
| 2023 Q3 | 7.6 Billion SEK | 6.01% |
| 2023 Q2 | 7.17 Billion SEK | 0.49% |
| 2023 FY | 31.82 Billion SEK | 12.5% |
| 2022 Q2 | 6.67 Billion SEK | 7.89% |
| 2022 Q1 | 6.18 Billion SEK | -22.61% |
| 2022 FY | 28.29 Billion SEK | 4.59% |
| 2022 Q4 | 8.49 Billion SEK | 22.43% |
| 2022 Q3 | 6.94 Billion SEK | 4.06% |
| 2021 Q1 | 6.16 Billion SEK | -30.21% |
| 2021 FY | 27.04 Billion SEK | -9.29% |
| 2021 Q2 | 6.58 Billion SEK | 6.78% |
| 2021 Q3 | 6.3 Billion SEK | -4.27% |
| 2021 Q4 | 7.98 Billion SEK | 26.67% |
| 2020 Q3 | 7.97 Billion SEK | 14.42% |
| 2020 FY | 29.81 Billion SEK | 12.27% |
| 2020 Q2 | 6.97 Billion SEK | 15.55% |
| 2020 Q1 | 6.03 Billion SEK | -29.01% |
| 2020 Q4 | 8.83 Billion SEK | 10.82% |
| 2019 Q4 | 8.49 Billion SEK | 36.27% |
| 2019 Q3 | 6.23 Billion SEK | -0.65% |
| 2019 Q1 | 5.54 Billion SEK | -29.68% |
| 2019 FY | 26.55 Billion SEK | 9.88% |
| 2019 Q2 | 6.27 Billion SEK | 13.14% |
| 2018 Q3 | 5.68 Billion SEK | -0.84% |
| 2018 FY | 24.17 Billion SEK | 7.45% |
| 2018 Q1 | 4.86 Billion SEK | 157.02% |
| 2018 Q2 | 5.73 Billion SEK | 17.73% |
| 2018 Q4 | 7.89 Billion SEK | 38.84% |
| 2017 Q4 | 1.89 Billion SEK | -71.71% |
| 2017 Q3 | 6.69 Billion SEK | -7.53% |
| 2017 FY | 22.49 Billion SEK | -24.4% |
| 2017 Q2 | 7.24 Billion SEK | 8.66% |
| 2017 Q1 | 6.66 Billion SEK | -30.02% |
| 2016 Q4 | 9.52 Billion SEK | 37.44% |
| 2016 Q1 | 6.37 Billion SEK | -32.28% |
| 2016 Q2 | 6.92 Billion SEK | 8.62% |
| 2016 FY | 29.75 Billion SEK | -1.58% |
| 2016 Q3 | 6.92 Billion SEK | 0.03% |
| 2015 FY | 30.23 Billion SEK | 13.37% |
| 2015 Q4 | 9.41 Billion SEK | 35.99% |
| 2015 Q3 | 6.92 Billion SEK | -3.56% |
| 2015 Q2 | 7.18 Billion SEK | 6.99% |
| 2015 Q1 | 6.71 Billion SEK | -20.9% |
| 2014 Q1 | 5.63 Billion SEK | -27.39% |
| 2014 FY | 26.66 Billion SEK | 5.47% |
| 2014 Q4 | 8.48 Billion SEK | 36.31% |
| 2014 Q3 | 6.22 Billion SEK | -1.61% |
| 2014 Q2 | 6.32 Billion SEK | 12.34% |
| 2013 Q4 | 7.75 Billion SEK | 32.6% |
| 2013 FY | 25.28 Billion SEK | 4.28% |
| 2013 Q3 | 5.85 Billion SEK | -2.74% |
| 2013 Q2 | 6.01 Billion SEK | 6.2% |
| 2013 Q1 | 5.66 Billion SEK | -27.52% |
| 2012 Q2 | 5.61 Billion SEK | 6.98% |
| 2012 Q3 | 5.57 Billion SEK | -0.68% |
| 2012 Q4 | 7.81 Billion SEK | 40.2% |
| 2012 FY | 24.24 Billion SEK | 10.95% |
| 2012 Q1 | 5.24 Billion SEK | -28.66% |
| 2011 Q3 | 4.86 Billion SEK | -1.95% |
| 2011 FY | 21.85 Billion SEK | -1.43% |
| 2011 Q1 | 4.67 Billion SEK | -29.66% |
| 2011 Q4 | 7.35 Billion SEK | 51.13% |
| 2011 Q2 | 4.96 Billion SEK | 6.25% |
| 2010 Q3 | 5.01 Billion SEK | -11.15% |
| 2010 Q2 | 5.64 Billion SEK | 16.16% |
| 2010 Q1 | 4.86 Billion SEK | -28.96% |
| 2010 FY | 22.17 Billion SEK | -2.82% |
| 2010 Q4 | 6.64 Billion SEK | 32.32% |
| 2009 FY | 22.81 Billion SEK | 18.39% |
| 2009 Q3 | 5.29 Billion SEK | -4.16% |
| 2009 Q4 | 6.84 Billion SEK | 29.3% |
| 2009 Q1 | 5.15 Billion SEK | 0.0% |
| 2009 Q2 | 5.52 Billion SEK | 7.2% |
| 2008 FY | 19.27 Billion SEK | 17.19% |
| 2007 FY | 16.44 Billion SEK | 26.49% |
| 2006 FY | 13 Billion SEK | 9.43% |
| 2005 FY | 11.88 Billion SEK | 9.11% |
| 2004 FY | 10.88 Billion SEK | 18.87% |
| 2003 FY | 9.16 Billion SEK | 6.02% |
| 2002 FY | 8.64 Billion SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -509866.352% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | -2218.063% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | -2218.063% |
| Arcoma AB | 163.01 Million SEK | -19423.97% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | -15502.235% |
| BICO Group AB (publ) | 2.23 Billion SEK | -1321.165% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | -5470.696% |
| CellaVision AB (publ) | 677.29 Million SEK | -4599.155% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | -384609.295% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -3259924.522% |
| C-Rad AB (publ) | 424.61 Million SEK | -7395.496% |
| Duearity AB (publ) | 1.65 Million SEK | -1924144.256% |
| Dignitana AB (publ) | 86.06 Million SEK | -36881.049% |
| Episurf Medical AB (publ) | 10.3 Million SEK | -308900.0% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | -449542.625% |
| Integrum AB (publ) | 104.11 Million SEK | -30468.016% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -3723667.081% |
| Mentice AB (publ) | 273.61 Million SEK | -11532.25% |
| OssDsign AB (publ) | 112.15 Million SEK | -28277.186% |
| Paxman AB (publ) | 210.11 Million SEK | -15047.275% |
| Promimic AB (publ) | 37.07 Million SEK | -85756.488% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -13043752.459% |
| SciBase Holding AB (publ) | 23.24 Million SEK | -136819.768% |
| ScandiDos AB (publ) | 60.42 Million SEK | -52568.421% |
| Sectra AB (publ) | 2.96 Billion SEK | -973.928% |
| Sedana Medical AB (publ) | 153.86 Million SEK | -20584.747% |
| Senzime AB (publ) | 35.75 Million SEK | -88916.614% |
| SpectraCure AB (publ) | 318 Thousand SEK | -10008390.566% |
| Stille AB | 294.89 Million SEK | -10692.728% |
| Vitrolife AB (publ) | 3.51 Billion SEK | -806.236% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | -5226.32% |